
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tolcapone
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The results confirm that CRX-1008 is a potent TTR stabilizer in both plasma and CSF using established ex vivo assays. CRX-1008 normalized TTR concentration in plasma with an overall mean increase in plasma TTR tetramer concentration of 55%.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 15, 2020
Lead Product(s) : Tolcapone
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tolcapone
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Quotient Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tolcapone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 16, 2018
Lead Product(s) : Tolcapone
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Quotient Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tolcapone
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Recipient : Boston University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tolcapone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Amyloidosis, Hereditary, Transthyretin-Related.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 19, 2018
Lead Product(s) : Tolcapone
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Recipient : Boston University
Deal Size : Inapplicable
Deal Type : Inapplicable
